alvarez
A Fast Take On Azitra
Azitra (AZTR) has filed to boost $17.25 million in an IPO of its widespread inventory, in keeping with an F-1 registration assertion.
The biopharma agency is growing drug therapy candidates for numerous pores and skin circumstances.
It has a product growth and investor relationship with Bayer Well being Care.
I’ll present a closing opinion once we be taught extra IPO particulars from administration.
Azitra Overview
Branford, Connecticut-based Azitra was based to develop a pipeline of drug candidates for the therapy of Netherton syndrome, papulopustular rash and ichthyosis vulgaris.
Administration is headed by president and CEO Francisco D. Salva, who has been with the agency since April 2021 and was beforehand president and CEO of Complexa, an irritation and fibrosis biopharma agency and was co-founder and vp of operations at Acerta Pharma B.V. He at the moment serves as a director of Vincerx Pharma (VINC)
The agency’s lead candidate, ATR-12, has been given the approval to proceed to Part 1b security trials which administration expects to start in Q1, 2023.
The 2 different medication are at a pre-clinical stage of growth.
Under is the present standing of the corporate’s drug growth pipeline:
Firm Pipeline (SEC)
Azitra has booked truthful market worth funding of $33.7 million as of December 31, 2022, from buyers together with Bios Fairness Entities, Bayer Well being Care and Connecticut Improvements.
Azitra’s Market & Competitors
In accordance with a 2021 market analysis report by ResearchAndMarkets, the worldwide marketplace for Netherton syndrome therapy was an estimated $19.6 million in 2019 and is forecast to succeed in $74.3 million by 2027.
This represents a forecast CAGR (Compound Annual Development Price) of 20.3% from 2021 to 2027.
Key components driving this anticipated progress are a rising consciousness of the illness and an growing variety of new therapy choices.
Additionally, the market is segmented into completely different remedy varieties:
-
Keratolytic brokers
-
Oral and topical steroids and retinoid
-
Topical calcineurin inhibitors
-
Organic therapies
-
Radiation therapies
Main aggressive distributors that present or are growing associated therapies embrace the next:
-
LifeMax Laboratories
-
Sixera Pharma Ab
-
Dermelix Biotherapeutics
-
MatriSys Bioscience
-
Quoin Prescribed drugs, Ltd. (QNRX)
-
Krystal Biotech (KRYS)
The corporate can be pursuing different pores and skin situation therapies in different markets.
Azitra Monetary Standing
The agency’s latest monetary outcomes are typical of an early-stage biopharma in that they characteristic no product gross sales income and materials R&D and G&A prices related to its growth efforts.
Under are the corporate’s monetary outcomes for the previous two years:
Assertion Of Operations (SEC)
As of December 31, 2022, the corporate had $3.5 million in money and $9.7 million in whole liabilities.
Azitra IPO Particulars
Azitra intends to boost $17.25 million in gross proceeds from an IPO of its widespread inventory, though the ultimate quantity might differ.
No current shareholders have indicated an curiosity to buy shares on the IPO worth, though this component might develop into a characteristic of the IPO if disclosed in a future submitting.
Administration says it should use the web proceeds from the IPO as follows:
IPO Use Of Proceeds (SEC)
Administration’s presentation of the corporate roadshow is just not out there.
Relating to excellent authorized proceedings, administration mentioned the agency is ‘not a celebration to any materials authorized proceedings.’
The only listed bookrunner of the IPO is ThinkEquity.
Commentary About Azitra’s IPO
AZTR is in search of public capital market funding to advance its pipeline of pores and skin situation therapies into and thru early-stage trials.
The agency’s lead candidate, ATR-12, has been given the approval to proceed to Part 1b security trials which administration expects to start in Q1, 2023.
The market alternative for the lead candidate is sort of small, though it’s anticipated to develop at a considerable price of progress within the coming years as new therapies develop into out there.
The agency can be growing therapy candidates for different pores and skin circumstances, probably with bigger market sizes.
Administration has a joint growth settlement With Bayer and the agency’s investor syndicate contains Bayer.
ThinkEquity is the only real underwriter and IPOs led by the agency during the last 12-month interval have generated a median return of destructive (35.1%) since their IPO. This can be a bottom-tier efficiency for all main underwriters in the course of the interval.
Once we be taught extra IPO particulars, I’ll present a closing opinion.
Anticipated IPO Pricing Date: To be introduced.
